Beyond Biotech - the podcast from Labiotech

Labiotech
  • 3.3 (3)
  • TECH NEWS
  • UPDATED WEEKLY

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

  1. 1D AGO

    Making labs smarter for scientific breakthroughs

    Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. Ryan's journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021. We'll explore the frustrations of fragmented lab tools that inspired Lab Thread's integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. We’ll uncover how it boosts reproducibility, ensures compliance, and frees scientists for innovation, with accessible pricing for academics and biotechs. I hope you enjoy Ryan’s insights on evolving digital workflows and accelerating breakthroughs in the lab. 01:51: Meet Ryan Cawood 02:31: Frustrations with early digital tools. 03:19: Daily lab organization challenges. 06:50: Time lost to admin tasks. 11:09: Genesis of the Lab Thread concept. 13:53: Integrated workflow functionality explained. 17:23: Enhancing experiment reproducibility methods. 20:37: Achieving compliance standards easily. 26:10: The future of digital lab management. 28:33: Accelerating scientific breakthroughs. This episode is brought to you with the support of Lab Thread. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Lab Thread - Your Lab, ConnectedHiding in plain sight: how to solve bioscience’s software problemLab chaos and digital dreams

    31 min

  2. APR 30

    How Epicrispr is leveraging CRISPR without cutting DNA

    This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr. Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector.  In this episode we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions.  01:43 Meet Stanley Qi03:32 Founding Epicrispr05:53 CRISPR interference and epigenome explained10:04 Overview of GEMS gene modulation system11:28 Reversibility and safety of epigenetic edits18:42 Strategy for tackling multiple disease conditions23:27 Clinical trial plans for EPI-321 candidate30:06 Looking forwardThis episode is brought to you with the support of MedChemExpress. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Could CRISPR really cure these diseases?10 gene therapy companies you should know aboutCRISPR technology’s next wave: Ten companies to watch

    33 min

  3. APR 24

    Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases

    Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he’s leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing symptoms. In this episode, Patrick walks us through his personal journey into science, the company’s DIAGONAL platform, and their lead program DIAG723, which recently received Orphan Drug Designation for the rare disease HHT, and is advancing toward the clinic. We also discuss Diagonal’s oversubscribed $125 million Series B financing that closed in January 2026, and what clustering antibodies could mean for patients with HHT, pulmonary arterial hypertension, and beyond. 01:33 Meet Patrick Andre08:01 Diagonal’s mission11:39 What are clustering antibodies16:05 Receptor clustering benefits for HHT and PAH20:24 Preclinical data on preventing and reversing HHT pathology22:39 The impact of the $125 Million Series B financing roundInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Vaderis emerges from stealth to start HHT trialPulmonary hypertension after Winrevair: where GSK’s $950M bet fitsNew treatment for pulmonary hypertension: what biotech holds in store?

    31 min

  4. APR 17

    Argobio: the venture model building Europe’s next biotech champions

    Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in pharma R&D, then as co-founder of Kurma Partners, and now leading Argobio’s unique venture-builder model. Since raising €50 million in 2021, Argobio has co-founded and accelerated several companies from top European academic labs. Three of them—Enodia, Laigo Bio, and Elkedonia—have already closed seed rounds totaling more than €43 million, advancing novel platforms in targeted protein degradation, precision membrane protein degraders, and non-hallucinogenic neuroplasticity enhancers for depression.  Thierry shares how Argobio reduces execution risk, embeds operational expertise, and turns promising science into investable companies that can compete worldwide.  04:02 Blending pharmacology expertise with business07:50 Vision behind starting Kurma Partners12:53 Launching Argobio to address gaps in European biotech 17:40 What makes the Argobio operational venture builder model unique25:02 Criteria for selecting academic scientific breakthroughs27:34 Changing dynamics of commercializing European research35:30 Europe vs US biotech investment climates37:47 Role of venture studios in Europe’s biotech futureInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  M Ventures: pharma CVC and biotech innovation in 2026Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giantsVenture capital co-creation: The next big thing in biotech investment?

    42 min

  5. APR 10

    Multi-agent AI delivers reliable and scalable insights for single-cell omics

    Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data. Our guest is Parashar Dhapola, co-founder and CEO of Nygen Analytics, a Lund-based startup spun out from Sweden's vibrant single-cell genomics ecosystem. With a PhD in computational genomics from Lund University, Parashar has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights for drug discovery. Join us as we discuss where AI truly delivers in biopharma, the persistent gaps in exploratory data analytics, and the critical bottlenecks in single-cell annotation. In a world abounding in AI hype, Parashar helps us cut through the noise and point out paths to data driven success. 01:00 Meet Parashar Dhapola05:45 AI in biopharma09:29 AI automation vs. new capabilities11:28 What makes single-cell omics data different18:46 Risks of incorrect cell annotation34:37 Future of single-cell analyticsThis episode is produced with the support of Nygen Analytics. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  CyteType - AI powered cell type annotationBehind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure?The past, present, and future of genome sequencing

    44 min

  6. APR 2

    Nionyx Bio's kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight

    This week we welcome Magdalena Tyrpien, CEO, Co-Founder and President of Nionyx Bio, just days after the company took first place in the BIO-Europe Spring Startup Spotlight competition in Lisbon. With a background that includes leading Forge Biologics through its $620 million acquisition, Magdalena is now steering Nionyx toward a bold new chapter in gene therapy for kidney disease. In this episode we explore her journey into biotech, the science behind Nionyx’s proprietary AAV capsid platform and Kidney Atlas, what it took to win the Startup Spotlight, and what the victory means for the young company’s future. ·  01:25 – Meet Magdalena Tyrpien ·  07:10 – The Nionyx mission ·  15:29 – The 2026 BIO-Europe Spring Startup Spotlight ·  22:23 – Looking forward and future milestones Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Lisbon is calling: the BIO-Europe Startup Spotlight returns in March 2026BIO-Europe Spring 2026: partnership event brings funding hope to biotechsBIO-Europe partnering: Australian biotech companies share their experiences

    29 min

  7. MAR 27

    HaemaLogiX - precision immunotherapy for multiple myeloma

    Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX, an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders. HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company's unique positioning in the field. Rosanne shares her journey from antibody engineering to building HaemaLogiX, the science behind their differentiated targets, the latest clinical and preclinical progress, and her perspectives on the future of immunotherapy for blood cancers as the company gears up for key milestones, including a planned IPO later this year. 01:15 Meet Rosanne Dunn07:52 HaemalogiX's mission and novel antigens09:53 Overview of multiple myeloma and its symptoms12:19 Targeting malignant plasma cells while sparing normal ones19:25 Recent Peer-Reviewed Research26:08 Synergy with IMiDs like Revlimid29:08 Potential patient impact and quality of life35:05 Planned IPO in 2026 and funding needsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  5 cancers that immunotherapy can cureBIO-Europe partnering: Australian biotech companies share their experiencesHow are R&D Tax Incentives shaping Australia’s biotech future?

    43 min

  8. MAR 20

    How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray

    Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, and Clarissa Koch, the company's Chief Scientific Officer. Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they published groundbreaking data in Science Translational Medicine, demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus's entry point: the nose. This innovation addresses the shortcomings of traditional flu vaccines, which average just 13% effectiveness against infection and provide even less for vulnerable groups like the elderly and immunocompromised. We'll dive into the science, the company's journey since its 2020 founding, and their recent €50 million European funding boost amid U.S. biotech challenges. 01:33: Meet Koenraad Wiedhaup 03:13: Meet Clarissa Koch 04:16: Leyden Labs' origin story 06:21: Mucosal protection platform explained 08:57: Complementing existing vaccines 11:47: Science of mucosal immunity 13:24: PanFlu lead candidate overview 16:42: Key findings from recent publication 22:02: Funding and future preparedness Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Seven biotech companies to know in the NetherlandsThe Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040 Influenza solution deals pile up as pandemic preparedness increases

    33 min
See All (196)

Ratings & Reviews

3.3
out of 5
3 Ratings

About

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

Information

You Might Also Like